FFA treatment can cause up-regulation of PPARγ via PGC1α in liver cells, and both PGC1α and PPARγ were elevated in the liver of mice with nonalcoholic fatty liver disease, a disease closely associated with obesity and HFD consumption [52]. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.